Skip to content
Catalyst

sulfonyldimethaneFinding

Sulfonyldimethane decreases WOMAC physical function subscale

lowersVery limited evidenceFinding

01 · The sentence it was drawn from

“Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05).”
Quoted verbatim from Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.
This finding among the 3 findings on its endpoint

sulfonyldimethane

WOMAC physical function subscale

lowers

Who
n = 50 · Fifty men and women, 40-76 years of age with knee osteoarthritis pain; WOMAC visual analogue scale format
Dose studied
MSM 3 g twice a day (6 g/day total) for 12 weeks

Very limited evidencePMID 16309928 · 2006

02 · The study

Study
RCT
Participants
50
Duration
3 months

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M71G4DCAZF78CQTNWP9S4T8J